Hillsdale Investment Management Inc. Invests $813,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Hillsdale Investment Management Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,800 shares of the biopharmaceutical company’s stock, valued at approximately $813,000.

Other large investors have also recently bought and sold shares of the company. Southland Equity Partners LLC raised its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 110 shares during the last quarter. Berkshire Bank raised its stake in Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 111 shares during the last quarter. CFO4Life Group LLC lifted its position in Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 112 shares during the period. GHP Investment Advisors Inc. lifted its position in Gilead Sciences by 1.1% during the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 122 shares during the period. Finally, J.W. Cole Advisors Inc. grew its stake in shares of Gilead Sciences by 1.0% in the 4th quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock valued at $1,256,000 after purchasing an additional 135 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GILD. Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $107.08 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a market capitalization of $133.35 billion, a price-to-earnings ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The stock has a fifty day moving average of $103.68 and a two-hundred day moving average of $93.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.95%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.